#Opdivo

FDA Approves Opdivo for Small Cell Lung Cancer

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.

The investigational machine has an 85% accuracy rate.

Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Could new cancer drugs restore immune responses against HIV?

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.

Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.

Two types of immunotherapy plus chemotherapy shrank tumors in most patients in an early study.

Cabometyx is the third liver cancer drug approved in the past six months.

A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.

Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.